Cilofungin

Echinocandin Antifungal (lipopeptide)Rx: ResearchCompound: Withdrawn

Also known as: Cilofungin, Echinocandin B p-octylphenyl ether, LY121019

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Cilofungin (LY121019) was the first echinocandin antifungal agent to enter clinical trials in humans. It demonstrated potent in vitro and in vivo activity against Candida species by inhibiting 1,3-beta-D-glucan synthase. Clinical development was halted in the late 1980s due to formulation-related toxicity (nephrotoxicity and polyethylene glycol vehicle toxicity) rather than intrinsic drug toxicity, paving the way for later echinocandins such as caspofungin, micafungin, and anidulafungin.

Mechanism of Action

Non-competitive inhibition of 1,3-beta-D-glucan synthase, disrupting fungal cell wall synthesis by blocking glucan polymer formation, leading to osmotic instability and fungal cell death

Routes of Administration

Intravenous

Goals & Uses

  • Treatment of invasive candidiasisAntifungalModerate
  • Treatment of disseminated fungal infectionsAntifungal TherapyLow
  • Prototype for echinocandin class developmentDrug DiscoveryHigh

Contraindications

  • Hypersensitivity to echinocandinsAllergyHigh
  • Renal impairmentOrgan DysfunctionHigh

Adverse Effects

  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
  • Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
  • Infusion-related reactionsHypersensitivityUncommon
  • NephrotoxicityRenalCommon

Drug Interactions

  • Nephrotoxic agentsHigh

Population Constraints

  • Pediatric patientsAgeRelative
  • Patients with renal impairmentOrgan ImpairmentAbsolute
  • Pregnant womenReproductiveRelative

Regulatory Status

  • European UnionUnapprovedNever received European regulatory approval; trials halted before submission
  • United StatesUnapprovedClinical development discontinued circa 1989; never submitted for FDA approval
  • United KingdomUnapprovedNo regulatory application made; compound remains a research reference only

Never received regulatory approval in any jurisdiction. Phase II clinical trials were discontinued circa 1989 due to vehicle-related toxicity (polyethylene glycol 400 solvent). Served as the prototype compound for the echinocandin class.

Evidence & Sources

No sources recorded yet.